Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company
"Antibody-Drug
Conjugate Pipeline Review by target, drug, phase and company"
The Report covers current Market Trends, Worldwide Analysis, Global
Forecast, Review, Share, Size, Growth, Effect.
Description-
The
competitive intelligence report „Antibody-Drug Conjugate Pipeline
Review by target, drug, phase and company“ evaluates and describes
the competitive landscape of antibody-drug conjugates (ADCs) in a
tabular format by target, payload, R&D phase and company as of
December 2016.
Purchase of the pdf report includes a 6-month
online access to the data of the report and any updates since the
publication date. Credentials to access the database will be sent by
e-mail and allow online work with the project data to print or export
an individual report.
Since
our last ADC Competitor Analysis in April 2013, the number of ADCs in
active clinical development has doubled from 33 in 2013 to 65 at the
end of the year 2016. Among them are eight ADCs in late stage
development or under regulatory review. More than 20 ADCs are in the
IND stage or undergoing IND-enabling studies. This analysis
identified further 58 preclinical stage ADC projects and 22 ADC
discovery programs. However, the number of ADCs discontinued from
clinical development also has increased.
The report furthermore lists the ADCs by
target, drug payload, and by company portfolio.
Among the popular targets of ADC developments identified in the search are:
Among the popular targets of ADC developments identified in the search are:
- Her2
- CD30
- CD33
- CD22
- CD19
- PSMA
- 5T4
- EGF-R
- CEACAM5
- CD37
- CD38
- CD25
- CD70
- Mesothelin
- c-Met
- MUC16
- CD123
- Tissue Factor
- TROP-2
- FGF-R
- Ephrin-A
in addition to unique targets identified
by companies with proprietary target discovery programs.
With the increasing number of ADCs in development
and of companies with in-house ADC technology development, new
payloads are being evaluated in early clinical studies.
The report includes a compilation of currently
active as well as discontinued ADC R&D. In addition, the report
lists company-specific R&D pipelines of ADCs.
Competitor projects are listed in a
tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound (antibody, linker, payload),
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments about latest results with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Comments
Post a Comment